Standard & Poor's will monitor these transactions, and post any relevant updates on its website: www.standardandpoors.com.
Advertisement
Masimo is a medical technology company. Headquartered in Irvine, CA, the company will be added to the S&P MidCap 400 GICS (Global Industry Classification Standard) Health Care Equipment Sub-Industry index.
Advertisement
Clearwater Paper is a pulp-based manufacturing company. Headquartered in Spokane, WA, the company will be added to the S&P SmallCap 600 GICS Paper Products Sub-Industry index.
Following is a summary of the changes:
Additions to and deletions from an S&P equity index do not in any way reflect an opinion on the investment merits of the companies concerned.
About Standard & Poor's Index Services
Standard & Poor's Index Services, the world's leading index provider, maintains a wide variety of investable and benchmark indices to meet an array of investor needs. Its family of indices includes the S&P 500, an index with $1.5 trillion invested and $4.85 trillion benchmarked, and the S&P Global 1200, a composite index comprised of seven regional and country headline indices. For more information, please visit www.standardandpoors.com/indices.
About Standard & Poor's
Standard & Poor's, a division of The McGraw-Hill Companies (NYSE: MHP), is the world's foremost provider of financial market intelligence, including independent credit ratings, indices, risk evaluation, investment research and data. With approximately 8,500 employees, including wholly owned affiliates, located in 23 countries and markets, Standard & Poor's is an essential part of the world's financial infrastructure and has played a leading role for more than 140 years in providing investors with the independent benchmarks they need to feel more confident about their investment and financial decisions. For more information, visit http://www.standardandpoors.com.
-- Masimo Corp. (Nasdaq: MASI) will replace PDL BioPharma Inc. (Nasdaq: PDLI) in the S&P MidCap 400 after the close of trading on Thursday, December 18. PDL BioPharma is spinning off its biotechnology operations in a transaction expected to be completed on or about that date. After the spin-off, PDL BioPharma will no longer be representative of the U.S. mid-cap space.
SOURCE Standard & Poor's
